Treatment response and prognosis factors in 48 patients with angioimmunoblastic T cell lymphoma
10.3760/cma.j.jssn.1673-4904.2016.06.022
- VernacularTitle:48例血管免疫母性T细胞淋巴瘤治疗及预后因素分析
- Author:
Jia LI
;
Zhuogang LIU
- Publication Type:Journal Article
- Keywords:
Lymphoma,T-cell;
Prognosis;
Retrospective studies
- From:
Chinese Journal of Postgraduates of Medicine
2016;39(6):554-558
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the influencing factors of therapeutic effect and prognosis in patients with angioimmunoblastic T cell lymphoma (AITL). Methods The clinical data of 48 patients with AITL were collected in order to evaluate its therapeutic effect and the influencing factors of prognosis. Results In the 48 patients with AITL, complete remission (CR) was in 15 cases, partial remission (PR) was in 16 cases, and the total effective rate was 64.58%(31/48). The recent total effective rate in patients of international prognostic index (IPI) score ≤2 scores was significantly higher than that in patients of IPI score >2 scores: 84.00% (21/25) vs. 43.48% (10/23), and there was statistical difference (P<0.05). The 1-year, 2-year and 3-year overall survival rates were 75.00%(36/48), 52.08%(25/48) and 35.42%(17/48), and the median survival time was 24.5 months. The patients of Ann Arbor stage Ⅰ-Ⅱ, IPI score ≤ 2 scores, Ki-67<50% and using CHOP combined with asparaginase (ASP) regimen had a higher 3-year overall survival rate compared with the patients of Ann Arbor stage Ann Arbor stage Ⅲ -Ⅳ, IPI score >2 scores, Ki-67 ≥ 50% and using CHOP regimen: 8/13 vs. 25.71%(9/35), 52.00% (13/25) vs. 17.39% (4/23), 55.00% (11/20) vs. 21.43% (6/28) and 48.28% (14/29) vs. 3/19, and there were statistical differences (P<0.05). Conclusions AITL is a kind of disease with poor prognosis. IPI score is the important influencing factor of recent therapeutic effect. The Ann Arbor stage, IPI score, Ki-67 levels and using contained ASP chemotherapy are the important factors of prognosis in patients with AITL.
